Merck uterine cancer drug meets late stage trial goals
Merck announced its drug sacituzumab tirumotecan met primary goals in a late-stage trial. The treatment helped patients live longer than those on chemotherapy.
Xurve View
Insights:
Xurve View
MERCK & CO. INC. reported its experimental drug sacituzumab tirumotecan met primary endpoints in a late-stage trial involving 776 uterine cancer patients. The treatment outperformed standard chemotherapy by extending survival and delaying disease progression in advanced cases. Positive Phase 3 data strengthens Merck's oncology pipeline as it seeks to diversify revenue beyond its existing blockbuster treatments.
